Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-001647-28
    Sponsor's Protocol Code Number:GO43075
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-08-05
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-001647-28
    A.3Full title of the trial
    A PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF GLOFITAMAB IN COMBINATION WITH RITUXIMAB (R) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN CIRCULATING TUMOR (ct)DNA HIGH-RISK PATIENTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA
    Estudio de fase II para evaluar la seguridad y la eficacia de glofitamab en combinación con rituximab (R) más ciclofosfamida, doxorubicina, vincristina y prednisona (CHOP) en pacientes de alto riesgo con linfoma difuso de células B grandes no tratado y ADN tumoral circulante (ADNtc)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination with Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating tumor (ct)DNA High-Risk Patients with Untreated Diffuse Large B-Cell Lymphoma
    Estudio para evaluar la seguridad y la eficacia de glofitamab en combinación con rituximab (R) más ciclofosfamida, doxorubicina, vincristina y prednisona (CHOP) en pacientes de alto riesgo con linfoma difuso de células B grandes no tratado y ADN tumoral circulante (ADNtc)
    A.4.1Sponsor's protocol code numberGO43075
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorRoche Farma S.A que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann-La Roche Ltd
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF.Hoffmann-La Roche Ltd.
    B.5.2Functional name of contact pointTrial Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number+34913257300
    B.5.5Fax number+34913248196
    B.5.6E-mailspain.start_up_unit@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGlofitamab
    D.3.2Product code RO7082859/F04-01
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGlofitamab
    D.3.9.3Other descriptive nameRO7082859
    D.3.9.4EV Substance CodeSUB197235
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Actemra®/RoActemra®
    D.2.1.1.2Name of the Marketing Authorisation holderRoche Registration GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTocilizumab
    D.3.2Product code RO4877533/F01-02
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTocilizumab
    D.3.9.1CAS number 375823-41-9
    D.3.9.3Other descriptive nameTOCILIZUMAB
    D.3.9.4EV Substance CodeSUB20313
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Diffuse Large B-Cell Lymphoma
    Linfoma difuso de células B grandes
    E.1.1.1Medical condition in easily understood language
    Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of cell that is responsible for producing antibodies.
    El linfoma difuso de células B grandes (DLBCL) es un cáncer de células B, un tipo de célula responsable de producir anticuerpos.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level PT
    E.1.2Classification code 10012818
    E.1.2Term Diffuse large B-cell lymphoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    • To evaluate the efficacy of glofitamab in combination with R-CHOP in circulating-tumor DNA (ctDNA) high-risk patients with previously untreated DLBCL based on end of treatment (EOT) complete response (CR) rate as determined by the investigator according to 2014 Lugano Response Criteria
    Evaluar la eficacia de glofitamab en combinación con R-CHOP en pacientes de alto riesgo con LDCBG no tratado previamente y ADNtc, basado en la tasa de respuesta completa (RC) al final del tratamiento (EOT) según lo determinado por el investigador de acuerdo con Criterios de respuesta de Lugano 2014.
    E.2.2Secondary objectives of the trial
    • To evaluate the efficacy of glofitamab in combination with R-CHOP in ctDNA high-risk patients with previously untreated DLBCL based on objective response rate (ORR) at the EOT, progression-free survival (PFS) and overall survival (OS) as determined by the investigator according to 2014 Lugano Response Criteria
    • To evaluate the safety of glofitamab in combination with R-CHOP in ctDNA high-risk participants with DLBCL
    • To characterize the serum pharmacokinetics (PK) profile of glofitamab in combination with R-CHOP
    • To evaluate potential effects of anti-drug antibodies (ADAs)
    - Evaluar la eficacia de glofitamab en combinación con R-CHOP en pacientes de alto riesgo con LDCBG no tratado previamente y ADNtc, basado en TRO al final del tratamiento (EOT) según lo determinado por el investigador conforme a los criterios de respuesta de Lugano de 2014.
    - Evaluar la eficacia de glofitamab en combinación con R-CHOP en pacientes de alto riesgo con LDCBG y ADNtc.
    - Caracterizar el perfil farmacocinético en suero de glofitamab en combinación con R-CHOP.
    - Evaluar los efectos potenciales de los ADAs (anti-drug antibodies)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Age >=18 years at the time of signing Informed Consent Form
    • Previously untreated patients with CD20-positive DLBCL, including one of the following diagnoses made according to the 2016 World Health Organization (WHO) classification of lymphoid neoplasms
    o DLBCL, not otherwise specified, including GCB and ABC/non-GCB types as well as double-expressor lymphoma (coexpression of MYC and BCL2)
    o High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 and/or BCL6 translocations
    o Patients with de novo transformed follicular lymphoma (patients with discordant bone marrow involvement, i.e., evidence of low-grade histology in bone marrow) may be considered after discussion with the Medical Monitor
    • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0–2
    • International Prognostic Index (IPI): 1-5
    • Life expectancy of >=6 months
    • Adequate biomarker blood samples prior to initiation of R-CHOP on Day 1 of Cycle 1 and on Day 1 of Cycle 2 submitted for screening for determination of ctDNA status
    • At least one bi-dimensionally fluorodeoxyglucose (FDG)-avid measurable lymphoma lesion on positron emission tomography/computed tomography (PET/CT) scan
    • Left ventricular ejection fraction (LVEF) >=50%, as determined on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
    • Adequate hematopoietic function
    • Contraception use
    Additional Inclusion Criterion for ctDNA High-Risk Participants
    • Plasma sample evaluated to be ctDNA high risk, defined as <2-log fold reduction in ctDNA levels between Day 1 of Cycle 1 and Day 1 of Cycle 2 by central laboratory assessment
    • Edad >=18 años en el momento de firmar el documento de consentimiento informado.
    • Pacientes con LDLBG CD20-positivo no tratados previamente, incluido uno de los siguientes diagnósticos según la clasificación de las neoplasias linfoides de la OMS de 2016.
    – LDLBG, sin especificar, incluidos los tipos GCB y ABC/no GCB, así como el linfoma con doble expresión (coexpresión de MYC y BCL2)
    Linfoma de linfocitos B de alto grado (LLBAG) con translocaciones de MYC y BCL2 o BCL6
    Podrá considerarse la participación de pacientes con linfoma folicular transformado de novo (pacientes con afectación discordante de la médula ósea, es decir, signos de histología de bajo grado en la médula ósea) previa consulta con el monitor médico.
    • Estado funcional del Eastern Cooperative Oncology Group (ECOG) de 0–2
    • Índice Pronóstico Internacional (IPI) 1-5
    • Esperanza de vida >= 6 meses.
    • Muestras de sangre adecuadas para análisis de biomarcadores antes del inicio de R-CHOP el día 1 del ciclo 1 y el día 1 del ciclo 2 enviadas para la selección a fin de determinar el estado del ADNtc.
    • Al menos una lesión linfomatosa mensurable en dos dimensiones con avidez por FDG en la PET/TC
    • Fracción de eyección del ventrículo izquierdo >= 50%, determinada mediante ventriculografía isotópica en equilibrio (MUGA) o ecocardiografía transtorácica.
    • Función hematopoyética adecuada
    • Uso de anticoncepción
    Criterio de inclusión adicional para pacientes de alto riesgo con ADNtc
    • Muestra de plasma considerada de alto riesgo con ADNtc, definida como una reducción logarítmica < 2 veces de la concentración de ADNtc entre el día 1 del ciclo 1 y el día 1 del ciclo 2 según la evaluación del laboratorio central.
    E.4Principal exclusion criteria
    • Current diagnosis of B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma (gray-zone lymphoma), primary mediastinal (thymic) large B-cell lymphoma, Burkitt lymphoma, central nervous system (CNS) lymphoma (primary or secondary involvement), primary effusion DLBCL, and primary cutaneous DLBCL
    • Contraindication to any of the individual components of R-CHOP, including prior receipt of anthracyclines, history of severe allergic or anaphylactic reactions to murine monoclonal antibodies, or known sensitivity or allergy to murine products
    • Prior treatment for indolent lymphoma
    • Prior solid organ or allogeneic stem cell transplant
    • Prior therapy for DLBCL and high-grade B-cell lymphoma (HGBCL) with the exception of palliative, short-term treatment with corticosteroids
    • Pregnant or breastfeeding, or intending to become pregnant during the study or within 12 months after the final dose of R-CHOP, 3 months after the final dose of tocilizumab (if applicable), or 2 months after the final dose of glofitamab
    • Diagnóstico actual de linfoma de linfocitos B, inclasificable, con características intermedias entre LDLBG y linfoma de Hodgkin clásico (linfoma de la zona gris), linfoma mediastínico primario de linfocitos B grandes (tímico), linfoma de Burkitt, linfoma del SNC (afectación primaria o secundaria), LDLBG con derrame primario y LDLBG cutáneo primario.
    • Contraindicación de cualquiera de los componentes individuales de R CHOP, como tratamiento previo con antraciclinas, antecedentes de reacciones alérgicas o anafilácticas graves a anticuerpos monoclonales murinos o sensibilidad o alergia conocidas a productos de origen murino.
    • Tratamiento previo del linfoma poco activo
    • Trasplante de órgano sólido o alotrasplante de células progenitoras previo (Trasplante previo de órganos sólidos o células madre alogénicas)
    • Tratamiento previo del LDLBG y el LLBAG con la excepción del tratamiento paliativo a corto plazo con corticosteroides.
    • Embarazo o lactancia, o intención de quedarse embarazada durante el estudio o en los 12 meses siguientes a la última dosis de R-CHOP, 3 meses después de la última dosis de tocilizumab (si procede) o 2 meses después de la última dosis de glofitamab.
    E.5 End points
    E.5.1Primary end point(s)
    1. EOT CR rate, as determined by the investigator according to the 2014 Lugano Response Criteria for Malignant Lymphoma
    1. Tasa de RC al FDT, según lo determinado por el investigador conforme a los criterios de respuesta de Lugano para el linfoma maligno de 2014.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1. Up to approximately 24 months
    1. Hasta aproximadamente 24 meses
    E.5.2Secondary end point(s)
    1. ORR at the EOT, as determined by the investigator according to the 2014 Lugano Response Criteria
    2. PFS, as determined by the investigator according to the 2014 Lugano Response Criteria
    3. OS
    4. Incidence and severity of adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
    5. Tolerability, as assessed by dose modifications, dose intensity, and study treatment discontinuation because of adverse events
    6. Serum concentrations of glofitamab at specified timepoints
    7. Serum trough concentrations of glofitamab at specified timepoints
    8. Maximum concentration (Cmax) of glofitamab at specified timepoints
    9. Area under the concentration–time curve (AUC) of glofitamab at specified timepoints
    10. Relationship between ADA status and efficacy, safety, or PK endpoints
    1.TRO al FDT, según lo determinado por el investigador conforme a los criterios de respuesta de Lugano de 2014.
    2.SLP, según lo determinado por el investigador conforme a los criterios de respuesta de Lugano de 2014.
    3.SG
    4.Incidencia e intensidad de los acontecimientos adversos, con determinación de la intensidad conforme a los criterios NCI-CTCAE v5.0.
    5.Tolerabilidad, evaluada mediante las modificaciones de la dosis, la intensidad de la dosis y la suspensión del tratamiento del estudio por acontecimientos adversos.
    6.Concentración sérica de glofitamab en momentos especificados.
    7.Concentración sérica mínima de glofitamab en momentos especificados.
    8. Concentración máxima (Cmax) de glofitamab en momentos específicos
    9. Área bajo la curva de concentración-tiempo (AUC) de glofitamab en momentos específicos
    10.Relación entre la presencia de ADA( ACF) y los criterios de valoración de eficacia, seguridad o farmacocinética
    E.5.2.1Timepoint(s) of evaluation of this end point
    1-3. Up to approximately 24 months
    4-5. Up to 90 days after the final dose of study treatment
    6-10. During treatment (up to approximately 10 months) and at treatment completion/discontinuation visit
    1-3. Hasta aproximadamente 24 meses
    4-5. Hasta 90 días después de la dosis final del tratamiento del estudio.
    6-10. Durante el tratamiento (hasta aproximadamente 10 meses) y en la visita de finalización / interrupción del tratamiento
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA15
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    Denmark
    France
    Netherlands
    Poland
    Spain
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    UVUP
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days13
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months1
    E.8.9.2In all countries concerned by the trial days13
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 40
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    A legally authorized representative will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50 (U.S. sites only), the ICH Guideline for Good Clinical Practice, and the IRB/EC.
    Se requerirá que un representante legalmente autorizado firme una declaración de consentimiento informado que cumpla con los requisitos de 21 CFR 50 (solo sitios de EE. UU.), La Guía de ICH para buenas prácticas clínicas y el IRB / EC.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 20
    F.4.2.2In the whole clinical trial 40
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Currently, the Sponsor does not have any plans to provide Roche glofitamab, rituximab, and tocilizumab or any other study treatments to participants who have completed the study. The Sponsor may evaluate whether to continue providing glofitamab, rituximab, and tocilizumab in accordance with the Roche Global Policy on Continued Access to Investigational Medicinal Product, available at the following website:
    http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
    Actualmente, el promotor no tiene planes de proporcionar glofitamab, rituximab y tocilizumab de Roche ni ningún otro tratamiento del estudio a los participantes que hayan completado el estudio. El promotor puede evaluar si continúa proporcionando glofitamab, rituximab y tocilizumab de acuerdo con la Política global de Roche sobre acceso continuo a medicamentos en investigación, disponible en el siguiente sitio web:
    http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-12-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-10-27
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 18:49:20 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA